Compare Advanced Micro Devices (AMD) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

AMD trades at $483.01, up 1.83% today, with strong earnings beats in recent quarters. The stock is near its 52-week high, supported by robust revenue growth and improving profitability. Technical indicators are neutral, with support at $479 and resistance at $489. Analysts maintain a bullish consensus, citing AI-driven demand for data center products.

Outlook remains positive due to AI expansion and market share gains, but high valuation multiples and intense competition pose risks. Upside is supported by a $619.54 consensus price target, though investors should monitor execution and macroeconomic headwinds.

INO trades at $0.9001, up 17.54% in the last session, but the technical outlook is bearish with key indicators like the 6-day RSI at 73.22 signaling overbought conditions. Fundamentally, the company reports minimal revenue of $65,340 in 2025 against a net loss of $84.95 million, reflecting a net income margin of -130,000%. Recent news highlights FDA review progress for INO-3107, with a PDUFA date set for October 30, 2026, representing a critical near-term catalyst.

The investment case hinges on the binary FDA decision for INO-3107, with a consensus price target of $3.25 implying significant upside if approved. However, high cash burn, persistent losses, and a bearish technical setup present substantial risks. Analyst sentiment is mixed with a 52.95% buy rating, but the stock remains a high-risk, event-driven play.